Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Status:
Completed

Trial end date:
2019-12-04

Target enrollment:

Participant gender:

This first-in-human, 3-stage, open-label study evaluated the safety and pharmacokinetics of ASTX727, as well as determined the dose for later stages.

Phase 1/Phase 2

Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.

Azacitidine
Decitabine